莫西沙星序贯治疗社区获得性肺炎的临床疗效观察

Clinical study on moxifloxacin in treatment of community acquired pneumonia

目的:观察莫西沙星序贯治疗社区获得性肺炎的临床疗效及安全性。方法:将72例社区获得性肺炎患者分成治疗组(36例)和对照组(36例)。治疗组给予莫西沙星注射液0.4g静脉滴注,每天1次,3～5d后患者临床症状有所改善改为口服莫西沙星片0.4g,每天1次,总疗程7～10d;对照组给予左氧氟沙星0.4g静脉滴注,每日1次,3～5d后患者临床症状有所改善改为口服左氧氟沙星片200mg,每日2次,总疗程7～10d。结果:治疗组痊愈率为66.67%(24例),显效率为27.78%(10例),好转率为5.56%(2例),无效率为0(0例),总有效率为94.44%;对照组痊愈率为58.33%(21例),显效率为30.56%(11例),好转率为8.33%(3例),无效率为2.78%(1例),总有效率为88.89%,两组疗效差异无统计学意义(Uc=0.7109,P=0.3992)。治疗组3例(8.33%)患者出现恶心、呕吐或眩晕;对照组4例(11.11%)患者出现恶心、呕吐或眩晕,两组比较差异无统计学意义(χ2=0.1587,P=0.6903)。结论:莫西沙星序贯治疗社区获得性肺炎有效,不良反应少。

Objective： To observe the efficacy and safety of moxifloxacin in the treatment of community acquired pneumonia. Methods： Senventy-two cases with community acquired pneumonia enrolled in the study were divided into treatment group （36 cases） and control group （36 cases）. Treatment group was treated with moxifloxacin in travenous infusion 0.4 g, one a day, after 3-5 days, the clinical symptoms improved to oral moxifloxacin piece of 0.4 g, one a day, total treatment 7 to 10 d; Control group was treated with levofloxacin in travenous infusion 0.4 g, one a day, after 3-5 days, the clinical symptoms improved after instead of oral levofloxacin 200 mg, 2 times a day, and total treatment 7 to 10 d; 2 times a day, and total treatment seven to 10 d. Results： The treatment group healed rate was 66.67% （24 cases）, powerfully rate of 27.78% （10 cases）, better rate of 5.56% （2 patients）, invalid rate of 0 （0 cases）, the total effective rate of 94.44%; Control group healed of 58.33% （21 cases）, powerfully rate of 30.56% （11 cases）, better rate of 8.33% （3 cases）, invalid rate of 2.78% （1 case）, the total effective rate of 88.89%, two groups was statistically significant differences （Uc=0.710 9, P=0.399 2）. In the treatment group, 3 cases （8.33%） experienced nausea, vomiting or dizziness, and the control group 4 cases （11.11%） were nausea, vomiting or dizziness, two groups of comparisons difference was statistically significant （χ2=0.158 7, P=0.690 3）. Conclusion： Moxifloxacin treat community-acquired pneumonia is effective, fewer side effects.